Sena Sert

Dr. Sena Sert


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2014 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
ACAltug Cincin
Altug Cincin
ISIbrahim Sari
Ibrahim Sari
MOMustafa Oğuz
Mustafa Oğuz
SSSena Sert
Sena Sert
MBMehmet Bozbay
Mehmet Bozbay
YBYelda Basaran
Yelda Basaran

1 January 2020 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
SSSena Sert
Sena Sert
MBMutlu Bulent
Mutlu Bulent
KDKocakaya Derya
Kocakaya Derya
KDKaptan Deniz
Kaptan Deniz
AHAtaş Halil
Ataş Halil
YBYıldızeli Bedrettin
Yıldızeli Bedrettin
Introduction: Lifelong anticoagulation is the cornerstone of the chronic thromboembolic pulmonary hypertension (CTEPH) treatment regardless of the additional pulmonary endarterectomy, balloon pulmonary angioplasty, or medical treatment alone. Aim of this study was to evaluate the rate of oral anticoagulant preferences and document direct oral anticoagulants’ (DOACs’) safety, efficacy in the CTEPH population.Methods: Patients’ demographic data obtained from database between September 2011 and April 2018. In‐hospital events, death, venous thromboembolism (VTE) recurrence, bleeding events and anticoagulant therapy transition were recorded.Results: We reviewed 501 CTEPH patients who observed 9.0 ± 8.5 years. All‐cause death, all bleeding, recurrent VTE was observed in 15.6%, 31% and 12%. Forty‐one patients (8.2%) were diagnosed as inoperable. Of all, 15.2% of operable patients remained as residual. All‐cause mortality rates were 13.8% (57 pts.) in the warfarin group as compared with 9.7% (13 pts.) in rivaroxaban group (HR: 1.61, 95% CI, 0.89–2.99; p: 0.11). Higher bleeding events occurred with warfarin group (27.1%) as compared with rivaroxaban (24.6%; HR: 1.28, 95% CI, 0.86–1.88; p: 0.22). Major bleeding was significantly higher with warfarin group (HR: 1.94, 95% CI, 1.05–3.62; p: 0.03). Subgroup analysis of all‐cause death revealed that this significance dominated by the rate of death according to bleeding events; warfarin versus those seen with rivaroxaban (4.85% vs. 2.2%; HR: 4.75, 95% CI: 1.12–20.16; p = 0.03). The rate of recurrent VTE was found 8.9% in the rivaroxaban group, 10.9% in warfarin group (HR: 1.21, 95% CI, 0.64–2.23; p: 0.55).Conclusion: DOACs could be a safe and effective alternative for lifelong anticoagulant therapy in CTEPH patients. Rivaroxaban produced similar rates of thromboembolism and non‐relevant bleeding compared to those associated with warfarin. The main difference was found with major bleeding that it was mainly associated with the death rate according to major bleeding. Using DOACs might be a more reasonable way to prevent bleeding events without increasing thromboembolic risk.

1 March 2017 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SSSena Sert
Sena Sert
HÖHasan Özdil
Hasan Özdil
MSMurat Sünbül
Murat Sünbül

16 June 2015 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
ACAltug Cincin
Altug Cincin
ISIbrahim Sari
Ibrahim Sari
MSMurat Sunbul
Murat Sunbul
AKAlper Kepez
Alper Kepez
MOMustafa Oguz
Mustafa Oguz
YBYelda Basaran
Yelda Basaran

29 July 2022 in Turkish Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
SSSena Sert
Sena Sert
NSNehir Selçuk
Nehir Selçuk
ÖYÖzlem Yıldırımtürk
Özlem Yıldırımtürk
GOGökçen Orhan
Gökçen Orhan
Background: In this study, we aimed to investigate the prognostic value of the tricuspid annular plane systolic excursion (TAPSE)/ pulmonary arterial systolic pressure (PASP) ratio in right ventricular failure patients undergoing left ventricular assist device implantation. Methods: Between February 2013 and February 2020, a total of 75 heart failure patients (65 males, 10 females; median age: 54 years; range, 21 to 66 years) were retrospectively analyzed. The prognostic value of TAPSE/PASP ratio was assessed using the multivariate Cox regression models and confirmed using the Kaplan-Meier analyses. Results: Forty-one (55.4%) patients had an ischemic heart failure etiology. The indication for assist device implantation was bridge to transplant in 64 (85.3%) patients. The overall survival rates at one, three, and five years following left ventricular assist device implantation were 82.7%, 68%, and 49.3%, respectively. Right ventricular failure was observed in 24 (32%) patients during follow-up. In the multivariate analysis, TAPSE/PASP was found to be independently associated with postoperative right ventricular failure (HR: 1.63; 95% CI: 1.49-2.23). A TAPSE/PASP of 0.34 mm/mmHg was found to be the most accurate predictor value, with lower ratios correlating with right ventricular failure. The Kaplan-Meier analysis showed a better overall survival using a TAPSE/PASP ? of 0.34 mm/mmHg (p<0.001). Conclusion: A lower TAPSE/PASP ratio, particularly lower values than 0.34 mm/mmHg, strongly predicts right ventricular failure after left ventricular assist device implantation in patients with advanced heart failure.

3 March 2015 in Echocardiography
Verified
Journal Article
Closed access
PDF file
ETElif T. Tigen
Elif T. Tigen
ISIbrahim SARI
Ibrahim SARI
KAKoray Ak
Koray Ak
SSSena Sert
Sena Sert
KTKursat Tigen
Kursat Tigen
VKVolkan Korten
Volkan Korten